Denali therapeutics announces new interim data from dnl310 phase 1/2 study for mps ii and dnl126 preclinical data for mps iiia at worldsymposium™

South san francisco, calif., feb. 22, 2023 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for the treatment of neurodegenerative diseases and lysosomal storage diseases, today announced new interim results from the ongoing open-label, single-arm phase 1/2 study of dnl310 (etv:ids) in children with mps ii (hunter syndrome), including data from additional participants and up to 104 weeks of treatment. dnl310 is an investigational brain-penetrant enzyme replacement therapy designed to address the behavioral, cognitive, and physical manifestations of mps ii. the interim phase 1/2 data are being presented at the 19th annual worldsymposium™ in orlando, florida, february 22-26, 2023.
DNLI Ratings Summary
DNLI Quant Ranking